Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …

METHODS Previously untreated CLL patients age< 70 years received three cycles of
ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD …

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …

PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …

Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …